Anti-CD55 / Decay Accelerating Factor (DAF), Monoclonal Antibody
| Product Name | Anti-CD55 / Decay Accelerating Factor (DAF), Monoclonal Antibody |
|---|---|
| Description | Recognizes a single chain glycoprotein of 70kDa, identified as CD55 (also known as decay accelerating factor, DAF). This monoclonal antibody was clustered in Kobe at the Sixth International Workshop on Human Leukocyte Differentiation Antigens as F429D-9 (N-L120). CD55/DAF is widely expressed on cells throughout the body including leukocytes, erythrocytes, epithelium, endothelium, and fibroblasts. It is a Glycosyl phosphatidylinositol anchored (GPI-anchored) member of the membrane bound complement regulatory proteins that inhibit autologous complement cascade activation. It prevents the amplification steps of the complement cascade by interfering with the assembly of the C3-convertases, C4b2a and C3bBb, and the C5-convertase, C4b2a3b and C3bBb3b. CD55 also serves as receptor for CD97 and for echovirus and Coxsackie B virus. Anti-CD55 can be used as marker for paroxysmal nocturnal hemoglobinuria (PNH). |
| Synonyms | CD55, CD55 Cromer blood group system, Complement decay-accelerating factor, CROM, DAF, Daf-GPI, Decay Accelerating Factor for Complement, Decay accelerating factor GPI-form, Decay accelerating factor soluble-form, GPI-DAF |
| Host | Mouse |
| Clonality | Monoclonal |
| Clone | F4-29D9 |
| Immunogen | Human umbilical vein endothelial cells (HUVEC) |
| Isotype | IgG1, kappa |
| Reactivity | Human |
| Applications | FC, IF |
| Form | 200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml. |
| Gene Id | 1604 |
| Uniprot | P08174 |
| Storage | Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required. |
| References | Schlossman S et al. (eds) Leukocyte Typing V. Oxford University Press, Oxford, 1995. Kishimoto T. et al., eds. Leukocyte Typing VI, Garland Publishing, Inc, New York and London, 1997.B.E. Loveland - in Leucocyte Typing VI - Part 6 Ð Known Non-Lineage CD Antigens - NL11 - CD55 Workshop Panel Report pp519-520, 199 |
| Supplier | ARP |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
